Helping innovative companies grow

Our Story


We started Asymmetry Group because we believe that asymmetric insights create the greatest advantage for businesses. We don’t believe in cookie-cutter approaches, benchmarking to the average, or simply recycling what worked for someone else. We want to create the right solutions for your business, whether you’re an early-stage firm with the next great product or service, or an established biopharma with billions in revenue. We work across therapeutic, medical device, diagnostic, and life sciences companies.

Simply put, we want to help extraordinary companies achieve outstanding results…and to play a small part in transforming healthcare along the way.

What makes us different?

Let’s be honest – there are many healthcare consultants out there. So, what makes Asymmetry Group different? Well, we believe we’re differentiated in several ways:

Practical experience in how your business operates (not just textbook knowledge, though we have that too), as we’ve held leadership roles in healthcare companies.

Deep healthcare expertise, particularly from pre-launch through market commercialization, with extensive expertise in rare disease and specialty pharmaceuticals.

Small, dedicated firm squarely focused on creating value for our clients.



Strong network of experts and firms that complement Asymmetry’s core expertise and can be selectively applied to projects.

Approach each engagement as unique, balancing prior learnings with your unique circumstances.


Simply put, we believe that asymmetric insights and approaches create the greatest advantage for businesses. We don’t believe in cookie-cutter approaches, benchmarking to the average, or recycling what worked for someone else. We want to help extraordinary companies achieve outstanding results.


Gregory Lief

Founder & Managing Director

Greg has devoted 20 years to growing healthcare companies through industry and management consulting experience. Prior to founding Asymmetry Group, Greg held a variety of leadership roles at Biogen, including heading the Global Commercial Excellence & Operations functions, serving as Chief of Staff to the Chief Commercial Officer, and developing several new-to-company functions including Launch Excellence, Marketing Excellence, Patient Insights and Digital Technology & Innovation. He has also held industry leadership positions in Corporate Strategy at Life Technologies and Supply Chain Strategy at Wyeth Biopharma. Through these experiences, Greg has become adept at quickly identifying issues and opportunities, creating new capabilities, and successfully implementing these in highly matrixed companies.

Greg also spent a decade in strategic management consulting at Monitor Group (now Deloitte Consulting), serving biopharmaceutical, medical device, diagnostic and life science clients. He has been based in multiple US locations, and lived in the United Kingdom serving European clients. Greg’s strategy work focused on product and franchise Commercial Strategy, Corporate Strategy, New Product Commercialization and Planning, and Business Development.

Greg has published articles and keynoted conferences. He holds an M.B.A. from the Kellogg School of Management at Northwestern University, and a B.A. in Biology and Environmental Studies from Dartmouth College.

Yakir Siegal

Managing Director

Yakir joined Asymmetry Group after serving as a Managing Director in the Monitor Deloitte Strategy practice of Deloitte Consulting. He has worked in a variety of industries since originally joining Monitor Group in 1994, including life sciences, energy, manufacturing, construction, consumer products, telecommunications, high technology, and financial services. Within these industries, he has worked on corporate and business unit strategy, commercial capability building, marketing and organic growth strategy, stakeholder management, new business development, leadership development, and organizational design.

In life sciences, Yakir’s 15+ years experience spans multiple therapeutic areas, including central nervous system, cardiovascular and metabolic, virology, oncology, hematology, urology, women’s health, and pain. His life sciences work covers the full range of the product lifecycle, from early commercial input through brand revitalization and lifecycle management and includes all aspects of integrated commercial strategy, ranging from market access and patient services to sales & marketing.

Yakir is a co-author of a number of articles on key topics in the life sciences and healthcare industry, including drug pricing and market access, a return on capital view of the US healthcare industry, and the role of business model innovation in MedTech.

Prior to his career as a strategy consultant, Yakir received an A.B., A.M., and Ph.D. in Physics from Harvard University, where his research focused on ultrafast laser spectroscopy, semiconductor physics, and nonlinear optics.

Raimonds Dzelme


Raimonds has worked in a broad range of roles within healthcare for the duration of his 20+ year career. As head of marketing at high growth organizations such as Collegium and Lundbeck, Raimonds has brought a disciplined approach to strategic and tactical planning with focused execution. Raimonds has led development of brand plans, innovative tactics, patient advocacy partnerships, media planning, and budget allocation based on exceeding financial goals.

Raimonds has launched numerous products across multiple therapeutic areas, including rare disease. Specifically, he led Xenazine (tetrabenazine) for chorea associated with Huntington’s Disease and Northera (droxidopa) for neurogenic orthostatic hypotension. Additionally, Raimonds led agency teams at Palio, Saatchi & Saatchi, and TargetRx where he closely collaborated with clients on numerous complex launches. Raimonds specializes in analyzing complex strategic situations and initiating innovative programs to drive sales beyond expectations.

Raimonds has worked across the US and in Europe. He holds an MBA from Thunderbird School of Global Management and a BS in Business from the University of the Pacific.